Capricor Therapeutics Inc Overview of CAP-1002 in Patients with Duchenne Muscular Dystrophy Transcript
¡ -
Good afternoon. I'm Linda Marbán, and I'm the CEO of Capricor Therapeutics. And today I'm going to be talking to you about an overview of CAP-1002 in patients with Duchenne muscular dystrophy.
We're a publicly traded company, Nasdaq listed, and our symbol is CAPR. So Capricor has been developing cell and exosome-based therapeutics for a few years now. We are a late-stage clinical development with CAP-1002 in Duchenne muscular dystrophy and have now presented very exciting data that I'll be sharing with you on our Phase 2 clinical trial for which we will be working with the FDA to try and get approval as quickly as possible.
Our exosome platform technology is being used not only to develop exosomes themselves as a therapeutic for Duchenne muscular dystrophy, but also we are using them as a platform to build therapeutics and vaccines for delivery. We are based in Los Angeles and I look forward to telling you the story of Capricor.
So Capricor's CAP-1002 technology is an allogeneic, which means off-the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
